Todd D Gould

List of Publications by Citations

Source: https://exaly.com/author-pdf/7904677/todd-d-gould-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

106 11,534 43 97 h-index g-index citations papers 106 6.57 13,192 7.9 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
97	The endophenotype concept in psychiatry: etymology and strategic intentions. <i>American Journal of Psychiatry</i> , 2003 , 160, 636-45	11.9	4393
96	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. <i>Nature</i> , 2016 , 533, 48	1 -5 0.4	903
95	The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. <i>Journal of Neuroscience</i> , 2003 , 23, 7311-6	6.6	414
94	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. <i>Pharmacological Reviews</i> , 2018 , 70, 621-660	22.5	395
93	Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. <i>Journal of Neuroscience</i> , 2004 , 24, 6590-9	6.6	345
92	Toward constructing an endophenotype strategy for bipolar disorders. <i>Biological Psychiatry</i> , 2006 , 60, 93-105	7.9	344
91	Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. <i>Neuropsychopharmacology</i> , 2005 , 30, 1223-37	8.7	303
90	AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7, 387-90	5.8	253
89	The mouse forced swim test. <i>Journal of Visualized Experiments</i> , 2012 , e3638	1.6	188
88	In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. <i>Neuropsychopharmacology</i> , 2004 , 29, 32-8	8.7	183
87	CACNA1C (Cav1.2) in the pathophysiology of psychiatric disease. <i>Progress in Neurobiology</i> , 2012 , 99, 1-1	4 10.9	179
86	Molecular effects of lithium. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2004 , 4, 259-72		159
85	Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 10-21	4.6	146
84	The Wnt signaling pathway in bipolar disorder. <i>Neuroscientist</i> , 2002 , 8, 497-511	7.6	133
83	Mood disorder susceptibility gene CACNA1C modifies mood-related behaviors in mice and interacts with sex to influence behavior in mice and diagnosis in humans. <i>Biological Psychiatry</i> , 2010 , 68, 801-10	7.9	131
82	Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. <i>Molecular Neurobiology</i> , 2005 , 32, 173-202	6.2	123
81	Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. <i>Molecular Psychiatry</i> , 2019 , 24, 1040-1052	15.1	123

(2008-2007)

80	Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. <i>Neuropsychopharmacology</i> , 2007 , 32, 2173-83	8.7	121	
79	Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. <i>Current Drug Targets</i> , 2006 , 7, 1399-409	3	106	
78	The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. <i>Neuroscience and Biobehavioral Reviews</i> , 2007 , 31, 932-62	9	102	
77	Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: a mouse model for the genetics of clinical response to lithium. <i>Neuropsychopharmacology</i> , 2007 , 32, 1321-33	8.7	101	
76	Signaling networks in the pathophysiology and treatment of mood disorders. <i>Journal of Psychosomatic Research</i> , 2002 , 53, 687-97	4.1	101	
75	Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. <i>Neuroscience and Biobehavioral Reviews</i> , 2007 , 31, 825-31	9	99	
74	Convergent Mechanisms Underlying Rapid Antidepressant Action. CNS Drugs, 2018, 32, 197-227	6.7	92	
73	Involvement of AMPA receptors in the antidepressant-like effects of lithium in the mouse tail suspension test and forced swim test. <i>Neuropharmacology</i> , 2008 , 54, 577-87	5.5	92	
72	Performance on a virtual reality spatial memory navigation task in depressed patients. <i>American Journal of Psychiatry</i> , 2007 , 164, 516-9	11.9	82	
71	Allergic rhinitis induces anxiety-like behavior and altered social interaction in rodents. <i>Brain, Behavior, and Immunity,</i> 2009 , 23, 784-93	16.6	79	
7º	Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 5160-5169	11.5	77	
69	The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015 , 355, 76-85	4.7	77	
68	Molecular actions and clinical pharmacogenetics of lithium therapy. <i>Pharmacology Biochemistry and Behavior</i> , 2014 , 123, 3-16	3.9	76	
67	LithiumS antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. <i>Annual Review of Pharmacology and Toxicology</i> , 2009 , 49, 175-98	17.9	75	
66	Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology, 2003 , 28, 1017-25	8.7	74	
65	()-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 6441-6450	11.5	73	
64	Motor neuron disease, TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked UBQLN2 mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E7580-E7589	11.5	65	
63	Generation and behavioral characterization of beta-catenin forebrain-specific conditional knock-out mice. <i>Behavioural Brain Research</i> , 2008 , 189, 117-25	3.4	62	

62	A Negative Allosteric Modulator for B Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice. <i>ENeuro</i> , 2017 , 4,	3.9	61
61	Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 359, 159-70	4.7	61
60	Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants. <i>Annual Review of Pharmacology and Toxicology</i> , 2019 , 59, 213-236	17.9	59
59	Altered performance on an ocular fixation task in attention-deficit/hyperactivity disorder. <i>Biological Psychiatry</i> , 2001 , 50, 633-5	7.9	55
58	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. <i>Psychopharmacology</i> , 2018 , 235, 3017-3030	4.7	53
57	Antidepressant-like responses to lithium in genetically diverse mouse strains. <i>Genes, Brain and Behavior</i> , 2011 , 10, 434-43	3.6	50
56	Mood stabilizer psychopharmacology. Clinical Neuroscience Research, 2002, 2, 193-212		47
55	Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. <i>Pharmacological Research</i> , 2003 , 48, 49-53	10.2	44
54	DARPP-32: A molecular switch at the nexus of reward pathway plasticity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 253-4	11.5	42
53	(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. <i>British Journal of Pharmacology</i> , 2019 , 176, 257	3 ⁸ 2592	₂ 38
52	Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. <i>Organic Letters</i> , 2017 , 19, 4572-4575	6.2	38
51	Dopamine and Stress System Modulation of Sex Differences in Decision Making. Neuropsychopharmacology, 2018 , 43, 313-324	8.7	35
50	The prodrug DHED selectively delivers 17 lestradiol to the brain for treating estrogen-responsive disorders. <i>Science Translational Medicine</i> , 2015 , 7, 297ra113	17.5	31
49	Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease. <i>PLoS ONE</i> , 2014 , 9, e87513	3.7	31
48	Group II metabotropic glutamate receptor blockade promotes stress resilience in mice. <i>Neuropsychopharmacology</i> , 2019 , 44, 1788-1796	8.7	29
47	Advances in multidisciplinary and cross-species approaches to examine the neurobiology of psychiatric disorders. <i>European Neuropsychopharmacology</i> , 2011 , 21, 532-44	1.2	29
46	Shock-induced aggression in mice is modified by lithium. <i>Pharmacology Biochemistry and Behavior</i> , 2010 , 94, 380-6	3.9	29
45	Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. <i>Expert Opinion on Therapeutic Targets</i> , 2006 , 10, 377-92	6.4	29

(2017-2018)

44	Intracellular Signaling Pathways Involved in (S)- and (R)-Ketamine Antidepressant Actions. <i>Biological Psychiatry</i> , 2018 , 83, 2-4	7.9	27
43	Lithium, but not valproate, reduces impulsive choice in the delay-discounting task in mice. <i>Neuropsychopharmacology</i> , 2013 , 38, 1937-44	8.7	26
42	(2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. <i>Neuropsychopharmacology</i> , 2020 , 45, 426-436	8.7	25
41	Reduced levels of Cacna1c attenuate mesolimbic dopamine system function. <i>Genes, Brain and Behavior</i> , 2017 , 16, 495-505	3.6	22
40	Immune status influences fear and anxiety responses in mice after acute stress exposure. <i>Brain, Behavior, and Immunity,</i> 2014, 38, 192-201	16.6	22
39	Decreased Nucleus Accumbens Expression of Psychiatric Disorder Risk Gene Cacna1c Promotes Susceptibility to Social Stress. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 428-433	5.8	22
38	Zanos et al. reply. <i>Nature</i> , 2017 , 546, E4-E5	50.4	21
37	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ()-hydroxynorketamine. <i>Journal of Psychopharmacology</i> , 2019 , 33, 12-24	4.6	21
36	Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. <i>Biological Psychiatry</i> , 2017 , 81, e69-e71	7.9	20
35	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 417-425	5.8	20
34	Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. <i>Neuropsychopharmacology</i> , 2020 , 45, 1398-140) \$.7	20
33	Sex-dependent modulation of age-related cognitive decline by the L-type calcium channel gene Cacna1c (Cav 1.2). <i>European Journal of Neuroscience</i> , 2015 , 42, 2499-507	3.5	17
32	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. <i>Pharmacological Reviews</i> , 2021 , 73, 763-791	22.5	17
31	Alpha2B-Adrenergic Receptor Overexpression in the Brain Potentiate Air Pollution-induced Behavior and Blood Pressure Changes. <i>Toxicological Sciences</i> , 2019 , 169, 95-107	4.4	13
30	Isoflurane but Not Halothane Prevents and Reverses Helpless Behavior: A Role for EEG Burst Suppression?. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 777-785	5.8	13
29	Affect-related behaviors in mice selectively bred for high and low voluntary alcohol consumption. <i>Behavior Genetics</i> , 2012 , 42, 313-22	3.2	13
28	Differential antidepressant-like response to lithium treatment between mouse strains: effects of sex, maternal care, and mixed genetic background. <i>Psychopharmacology</i> , 2013 , 228, 411-8	4.7	12
27	Ketamine Mechanism of Action: Separating the Wheat from the Chaff. <i>Neuropsychopharmacology</i> , 2017 , 42, 368-369	8.7	11

26	Sex-Specific Involvement of Estrogen Receptors in Behavioral Responses to Stress and Psychomotor Activation. <i>Frontiers in Psychiatry</i> , 2019 , 10, 81	5	11
25	Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens. <i>Journal of Neurochemistry</i> , 2016 , 139, 576-585	6	11
24	Cigarette smoke and nicotine effects on brain proinflammatory responses and behavioral and motor function in HIV-1 transgenic rats. <i>Journal of NeuroVirology</i> , 2018 , 24, 246-253	3.9	10
23	Effect of lithium on behavioral disinhibition induced by electrolytic lesion of the median raphe nucleus. <i>Psychopharmacology</i> , 2015 , 232, 1441-50	4.7	8
22	Psychological stress enhances tumor growth and diminishes radiation response in preclinical model of lung cancer. <i>Radiotherapy and Oncology</i> , 2020 , 146, 126-135	5.3	8
21	Neurotrophic signaling cascades are major long-term targets for lithium: clinical implications. <i>Clinical Neuroscience Research</i> , 2004 , 4, 137-153		8
20	Ketamine and the Future of Rapid-Acting Antidepressants. <i>Annual Review of Clinical Psychology</i> , 2021 , 17, 207-231	20.5	8
19	Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. <i>Journal of Affective Disorders</i> , 2021 , 280, 136	s-6 5 9	8
18	Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma. <i>Pharmacology Biochemistry and Behavior</i> , 2020 , 196, 172973	3.9	7
17	GSK-3 and neurotrophic signaling: novel targets underlying the pathophysiology and treatment of mood disorders?. <i>Drug Discovery Today Disease Mechanisms</i> , 2004 , 1, 419-428		7
16	Mechanisms of Ketamine and its Metabolites as Antidepressants <i>Biochemical Pharmacology</i> , 2021 , 114	892	7
15	F102. Human Experimenter Sex Modulates Mouse Behavioral Responses to Stress and to the Antidepressant Ketamine. <i>Biological Psychiatry</i> , 2018 , 83, S277	7.9	6
14	Classical conditioning of antidepressant placebo effects in mice. <i>Psychopharmacology</i> , 2020 , 237, 93-10	2 _{4.7}	5
13	Antidepressant Effects and Mechanisms of Group II mGlu Receptor-Specific Negative Allosteric Modulators. <i>Neuron</i> , 2020 , 105, 1-3	13.9	4
12	A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. <i>Neurotoxicology and Teratology</i> , 2021 , 87, 106993	3.9	4
11	Irving I. Gottesman (1930-2016): the multifactorial threshold model of complex phenotypes mediated by endophenotype strategies. <i>Genes, Brain and Behavior</i> , 2016 , 15, 775-776	3.6	2
10	Differential lithium efficacy in reducing suicidal behaviors compared with suicidal thoughts. <i>American Journal of Psychiatry</i> , 2012 , 169, 98-9; author reply 99	11.9	2
9	(R,S)-ketamine and (2R,6R)-hydroxynorketamine differentially affect memory as a function of dosing frequency. <i>Translational Psychiatry</i> , 2021 , 11, 583	8.6	2

LIST OF PUBLICATIONS

8	Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders. <i>Current Signal Transduction Therapy</i> , 2007 , 2, 101-110	0.8	2
7	Effects of environmental stress following myocardial infarction on behavioral measures and heart failure progression: The influence of isolated and group housing conditions. <i>Physiology and Behavior</i> , 2015 , 152, 168-74	3.5	1
6	7B2 chaperone knockout in APP model mice results in reduced plaque burden. <i>Scientific Reports</i> , 2018 , 8, 9813	4.9	1
5	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (26)- and (5)-Methyl-(26)-hydroxynorketamines <i>ACS Chemical Neuroscience</i> , 2022 ,	5.7	1
4	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration <i>Translational Psychiatry</i> , 2022 , 12, 179	8.6	1
3	Avances en enfoques multidisciplinarios y en diversas especies para el examen de la neurobiolog de los trastornos psiqui l ricos. <i>Psiquiatria Biologica</i> , 2012 , 19, 9-20	0.2	O
2	Sex-dependent metabolism of ketamine and ()-hydroxynorketamine in mice and humans <i>Journal of Psychopharmacology</i> , 2021 , 2698811211064922	4.6	O
1	(2R,6R)-hydroxynorketamine rapidly potentiates optically-evoked Schaffer collateral synaptic activity. <i>Neuropharmacology</i> , 2022 , 214, 109153	5.5	O